Payment overview · 2025
General Payments
$439.45
22 reported records · 11 companies
Healthcare provider profile · identity verified
Denise R Dingle, MD
Allopathic & Osteopathic Physicians|Family Medicine · SMITHVILLE, TN · NPI 1518974732
Verified facts
What the public records show
CMS Open Payments records show Denise R Dingle, MD received $439.45 in general payments during 2025 across 22 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $122.54 | 27.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $85.59 | 19.5% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.15 | 10.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.42 | 7.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.54 | 7.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.63 | 6.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.34 | 5.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.94 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.44 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.20 | 3.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.66 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.45 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $122.54 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.59 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.15 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.54 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 500 | 72 |
| Gabapentin | Gabapentin | 485 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 410 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 91 |
| Omeprazole | Omeprazole | 354 | 86 |
| Lisinopril | Lisinopril | 340 | 95 |
| Furosemide | Furosemide | 274 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 57 |
| Potassium Chloride | Potassium Chloride | 194 | 50 |
| Allopurinol | Allopurinol | 175 | 32 |
| Metformin Hcl | Metformin Hcl | 170 | 34 |
| Losartan Potassium | Losartan Potassium | 166 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 49 |
| Eliquis | Apixaban | 157 | 17 |
| Baclofen | Baclofen | 155 | 29 |
| Pregabalin | Pregabalin | 136 | 16 |
| Ozempic | Semaglutide | 134 | 20 |
| Famotidine | Famotidine | 133 | 36 |
| Alprazolam | Alprazolam | 130 | 20 |
| Trazodone Hcl | Trazodone Hcl | 123 | 32 |
| Azithromycin | Azithromycin | 121 | 75 |
| Simvastatin | Simvastatin | 121 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 119 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 31 |
| Divalproex Sodium | Divalproex Sodium | 95 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 94 | 31 |
| Prednisone | Prednisone | 94 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 22 |
| Clonazepam | Clonazepam | 91 | 16 |
| Ibuprofen | Ibuprofen | 90 | 34 |
| Spironolactone | Spironolactone | 89 | 25 |
| Tramadol Hcl | Tramadol Hcl | 88 | suppressed |
| Dexamethasone | Dexamethasone | 87 | 62 |
| Carvedilol | Carvedilol | 86 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 35 |
| Sertraline Hcl | Sertraline Hcl | 86 | 25 |
| Mirtazapine | Mirtazapine | 85 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 24 |
| Donepezil Hcl | Donepezil Hcl | 80 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 74 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 15 |
| Meloxicam | Meloxicam | 71 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 71 | 11 |
| Buspirone Hcl | Buspirone Hcl | 70 | 17 |
| Memantine Hcl | Memantine Hcl | 69 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 13 |
| Jardiance | Empagliflozin | 67 | suppressed |
| Lovastatin | Lovastatin | 67 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 24 |
| Lorazepam | Lorazepam | 66 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | suppressed |
| Amoxicillin | Amoxicillin | 64 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 22 |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 20 |
| Fluconazole | Fluconazole | 55 | 23 |
| Clonidine Hcl | Clonidine Hcl | 54 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 39 |
| Chlorthalidone | Chlorthalidone | 52 | 13 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 17 |
| Nystatin | Nystatin | 51 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | 13 |
| Nitroglycerin | Nitroglycerin | 47 | 27 |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 15 |
| Cefdinir | Cefdinir | 40 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | 12 |
| Estradiol | Estradiol | 39 | 14 |
| Glimepiride | Glimepiride | 38 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | 13 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 21 |
| Celecoxib | Celecoxib | 34 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Atenolol | Atenolol | 33 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Bumetanide | Bumetanide | 32 | suppressed |
| Linzess | Linaclotide | 32 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Kerendia | Finerenone | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Vilazodone Hcl | Vilazodone Hcl | 21 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Cholestyramine Light | Cholestyramine | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benzonatate | Benzonatate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.45 · 22 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, JOURNAVX, Kerendia, MOUNJARO, Ohtuvayre, QULIPTA, REXULTI, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error